ArriVent BioPharma, Inc. (AVBP)
Healthcare
Biotechnology
29.80 $
-2.7%
vs. previous close
Closing price · As of: 31. Jul 2026
ArriVent BioPharma, Inc. (AVBP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -161 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| -13 | -44 | -56 | -70 | -161 | |
| – | – | – | – | -3.0 | |
| 0.1 | 0.4 | 0.9 | 3.2 | 13 | |
| -3.9 | -7.1 | 13 | 7.1 | -3.8 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -40 | – | – | -192 | -71 | |
| – | 0.0 | – | – | – | |
| 90 | 170 | 43 | 187 | 203 | |
| 37 | 126 | -13 | -76 | -29 | |
| -13 | -44 | -56 | -70 | -161 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.